| 1. |
- Parkinson, Chrysa, 1964-
(författare)
-
Dance as Practice
- 2019
-
Ingår i: Etcetera. - Brussels : Etcetera. - 0774-2738. ; 158
-
Tidskriftsartikel (refereegranskat)abstract
- De verzameling van voorstellingen die een choreograaf of een theaterregisseur heeft gemaakt, noemen we – tenminste als er een zekere consensus bestaat over het artistieke belang ervan – een oeuvre. Wat bouwen dansers en acteurs op tijdens hun professionele loopbaan? Welke symbolische en economische waarde genereert hun kunde? Zijn zij als uitvoerende kunstenaars ook ‘auteurs’? Een gesprek met Chrysa Parkinson, danseres voor onder meer Boris Charmatz, Anne Teresa De Keersmaeker, Jonathan Burrows en Eszter Salamon, danspedagoge aan P.A.R.T.S. en directeur van de performanceafdeling van DOCH Uniarts in Stockholm.
|
|
| 2. |
- Parkinson, Chrysa, 1964-
(creator_code:cre_t, dialog)
-
THE VALUE OF DANCE AS PRACTICE
- 2016
-
Ingår i: Audio Stage, a deep dive into artistic minds. - Melbourne : Audio Stage/Guerilla Semiotics.
-
Tidskriftsartikel (refereegranskat)abstract
- In the first episode of season three, Angela and Jana speak to Chrysa Parkinson on the creativity of the dancer: the work of dance, the authorship of the dancer, and whether excessive praise is how we pay artists in lieu of a living wage.
|
|
| 3. |
- Pavic, Kristina, et al.
(författare)
-
Discovery of harmiprims, harmine-primaquine hybrids, as potent and selective anticancer and antimalarial compounds
- 2024
-
Ingår i: Bioorganic & Medicinal Chemistry. - : Elsevier. - 0968-0896 .- 1464-3391. ; 105
-
Tidskriftsartikel (refereegranskat)abstract
- Although cancer and malaria are not etiologically nor pathophysiologically connected, due to their similarities successful repurposing of antimalarial drugs for cancer and vice-versa is known and used in clinical settings and drug research and discovery. With the growing resistance of cancer cells and Plasmodium to the known drugs, there is an urgent need to discover new chemotypes and enrich anticancer and antimalarial drug portfolios. In this paper, we present the design and synthesis of harmiprims, hybrids composed of harmine, an alkaloid of the beta-carboline type bearing anticancer and antiplasmodial activities, and primaquine, 8-aminoquinoline antimalarial drug with low antiproliferative activity, covalently bound via triazole or urea. Evaluation of their antiproliferative activities in vitro revealed that N-9 substituted triazole-type harmiprime was the most selective compound against MCF-7, whereas C1-substituted ureido-type hybrid was the most active compound against all cell lines tested. On the other hand, dimeric harmiprime was not toxic at all. Although spectrophotometric studies and thermal denaturation experiments indicated binding of harmiprims to the ds-DNA groove, cell localization showed that harmiprims do not enter cell nucleus nor mitochondria, thus no inhibition of DNArelated processes can be expected. Cell cycle analysis revealed that C1-substituted ureido-type hybrid induced a G1 arrest and reduced the number of cells in the S phase after 24 h, persisting at 48 h, albeit with a less significant increase in G1, possibly due to adaptive cellular responses. In contrast, N-9 substituted triazole-type harmiprime exhibited less pronounced effects on the cell cycle, particularly after 48 h, which is consistent with its moderate activity against the MCF-7 cell line. On the other hand, screening of their antiplasmodial activities against the erythrocytic, hepatic, and gametocytic stages of the Plasmodium life cycle showed that dimeric harmiprime exerts powerful triple-stage antiplasmodial activity, while computational analysis showed its binding within the ATP binding site of PfHsp90.
|
|
